FY23 FCF collapsed to $12.5m as capex stepped up 53%

The decline was concentrated in the first half: H2 revenue grew 14% to $890.5m (12% in constant currency), so 56% of full-year revenue and 62% of NPAT came in the second half.

Cash generation deteriorated more than earnings. Operating cash flow fell 26.5% to $238.2m, while capex rose 52.7% to $211.3m, pushing pre-lease FCF down to $26.9m from $185.9m and post-lease FCF to $12.5m. Hospital revenue fell to $1b and its share of revenue dropped to 64.7% from 72.0%; Homecare grew to $553.8m, taking share to 35.0%.

Payout ratio versus pre-lease FCF is suppressed because the source-backed cash-dividend bridge is unavailable.

Capex moved to 13.4% of revenue from 8.2%, a level more consistent with capacity build for a higher demand base than with steady-state replacement. Whether this is a transitional catch-up after the COVID-era hardware pull-forward or a new run-rate is the central question for forward FCF, because it directly determines how quickly the dividend regains cash cover.

H2 provides a cleaner read on underlying demand than the headline. Constant-currency growth of 12% in the second half, with management citing Hospital new applications consumables and OSA masks, suggests the post-COVID hardware comparable has largely washed through. The reported -6.0% full-year number is dominated by the H1 base effect rather than current trading.

Annualising H2 revenue gives an indicative pace around $1.8b, but seasonality, FX and the timing of Hospital hardware re-orders make a straight extrapolation unreliable. The release does support a read that volumes are recovering, particularly in Homecare and consumables; it does not support a read that cash generation is recovering at the same pace.

The gap matters because the FY23 capital allocation pattern – capex up 53%, FCF near zero, dividend funded from balance sheet – is not sustainable for long without either a step-down in capex intensity or a faster recovery in operating margins than H2 revenue alone implies.

The effective tax rate was 23.7% vs 25.2%, and PBT growth (-34.9%) and NPAT growth (-33.6%) are only 1.3pp apart, so the read on underlying performance is clean. ROE fell to 14.3% from 22.4%, consistent with a real margin contraction rather than a presentation effect.

Working capital absorbed a meaningful share of operating cash. Receivable days extended to 41.5 from 31.0, inventory days to 84.4 from 77.9, and operating working capital rose $43.7m. Together with the 52.7% capex step-up, this is where the gap between $250.3m NPAT and $12.5m FCF sits. The lower-quality elements – debtor extension, inventory build, capex acceleration – are concentrated on the cash side rather than in reported profit, so the durability question is about future FCF rather than future EPS.

This briefing cannot assess gross margin movement, currency impact on margins, or product-line profitability because those disclosures are not in the supplied data.